Table 2.

Real-world ORR with 1L lenvatinib

	Cohort 1		Cohort 2
	n = 71		n = 181
	N	%	n	%
ORR† (%)	46	64.8	97	53.6
CR	6	8.5	3	1.7
PR	40	56.3	94	51.9
SD	10	14.1	45	24.9
PD	10	14.1	26	14.4
Not evaluable	5	7.0	13	7.2

1L first-line, CR complete response, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease

^†Per RECIST v1.1 criteria; see “Methods”